Bladder-Delivered FimH Nanoparticle Vaccine for Recurrent UTI Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for urinary tract infections (UTIs) lack effective adjuvants to boost immunogenicity and induce protective immunity, and parenteral delivery methods fail to evoke adequate antibody production and bacteria-clearing T cells in the bladder.
Innovation Solution
A recombinant vaccine composition comprising a truncated fimbrial protein (amino acids 1-163 of FimH) combined with a Th1-skewing adjuvant, such as CpG oligodeoxynucleotide, monophosphoryl lipid A, or imiquimod, incorporated into biodegradable nanoparticles, is administered locally to the bladder to stimulate a T helper cell 1 (Th1) response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional parenteral vaccine delivery is used, then vaccine administration is simple, but inadequate antibody production and bacteria-clearing T cells are evoked in the bladder
Solution Approach 1:
The patent uses biodegradable nanoparticles as an intermediary carrier to deliver the vaccine composition directly to the bladder. The nanoparticles facilitate localized delivery of the truncated fimbrial protein and adjuvant, enabling effective immunogenicity in the bladder while avoiding the complexity of direct bladder injection procedures.
Solution Approach 2:
The patent implements local quality by delivering the vaccine composition specifically to the bladder tissue rather than systemic administration. This localized delivery ensures high concentration of the vaccine at the target site, evoking adequate antibody production and bacteria-clearing T cells in the bladder while minimizing systemic side effects.
2Reliability
If traditional adjuvants are used, then vaccine formulation is simple, but protective immunity is not adequately boosted
Solution Approach 1:
The patent employs composite materials by combining the truncated fimbrial protein antigen with Th1-skewing adjuvants (such as CpG oligodeoxynucleotide, monophosphoryl lipid A, or imiquimod) within a biodegradable nanoparticle matrix. This composite formulation synergistically enhances protective immunity by simultaneously providing antigen delivery and immune stimulation.
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical properties of the vaccine formulation through nanoparticle encapsulation. The nanoparticle size, surface charge, and degradation rate are optimized to enhance cellular uptake, prolong antigen release, and improve adjuvant effectiveness, thereby boosting protective immunity.
3Reliability
If full-length FimH protein is used, then antigen completeness is maintained, but immunogenicity and T cell response are insufficient
Solution Approach 1:
The patent applies the extraction principle by using a truncated version of the FimH protein (amino acids 1-163) that contains the critical antigenic determinants and T cell epitopes while removing portions that may hinder immunogenicity or complicate the structure. This truncated antigen maintains essential immunogenic properties while enhancing T cell response when combined with Th1-skewing adjuvants.
Data Source
AI summary
Disclosed herein are vaccine compositions for the treatment and prevention of urinary tract infections (UT!s) and methods for delivery of the vaccine compositions. Moreover, the disclosure provides adjuvant compositions for vaccines to modulate cellular responses, such as an immune response.